Skip to main content

Table 3 Summary of clinical trials involving PARPis

From: PARP inhibitors in gastric cancer: beacon of hope

Sensitization Study Title Status Intervention Most advanced clinical phase Setting Trial identifier
PARPis synergistic members
Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations Not yet recruiting Talazoparib II Clinical Stage III/ IV Gastric Cancer AJCC v8 NCT04550494
Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric Cancer Active, not recruiting pamiparib II Advanced or Inoperable Gastric Cancer NCT03427814
A Study to Evaluate Rucaparib in Patients With Solid Tumors and With Deleterious Mutations in HRR Genes (LODESTAR) Recruiting Rucaparib II stomach cancer NCT04171700
A Translational Study of Single Agent Olaparib in the Treatment of Advanced Oesophagogastric Cancer (SOLAR) Recruiting Olaparib II Gastric and oesophageal cancers NCT03829345
A Study Evaluating Safety and Efficacy of Niraparib in Patients With Previously Treated Metastatic Esophageal/Gastroesophageal Junction/Proximal Gastric Adenocarcinoma Recruiting Niraparib II Gastric Cancer NCT03840967
chemotherapy Efficacy Study of Olaparib With Paclitaxel Versus Paclitaxel in Gastric Cancer Patients Active, not recruiting olaparib paclitaxel II Recurrent or Metastatic Gastric Cancer Who Progress Following First-line Therapy NCT01063517
A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid Tumors Completed Veliparib Carboplatin, Paclitaxel, FOLFIRI I Gastric Cancer NCT02033551
A Study of Fluzoparib Given in Combination With Apatinib and Paclitaxel in Gastric Cancer Patients NA Fluzoparib Apatinib, Paclitaxel I Recurrent and Metastatic Gastric Cancer NCT03026881
Evaluating the Safety and Tolerability of the Poly-ADP Ribose (PARP) Inhibitor With FOLFIRI in Subjects With Solid Tumor Completed Veliparib FOLFIRI I Gastric Cancer NCT01123876
Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer Active, not recruiting Olaparib Paclitaxel III Gastric Cancer NCT01924533
A Phase 1b Study to Assess the Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Subjects With Locally Advanced or Metastatic Solid Tumors Recruiting BGB-290 Temozolomide I/II Gastric Cancer NCT03150810
antiangiogenic agents Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery Recruiting Olaparib Ramucirumab I/II Metastatic or Locally Recurrent Gastric cancer NCT03008278
ATR Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents Recruiting Olaparib ceralasertib I/II Gastric Cancer NCT02264678
immunotherapy Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid Tumors (ARIANES) Recruiting Rucaparib Atezolizumab II Gastric or gastro-esophageal junction adenocarcinoma NCT04276376
The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors Completed BGB-290 tislelizumab I/Ib (HER2)-negative gastric or gastroesophageal junction cancer NCT02660034
A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors (MEDIOLA) Active, not recruiting Olaparib MEDI4736 I/II Metastatic or relapsed Gastric cancer (adenocarcinoma) NCT02734004
A Study of Niraparib Combined With MGD013 in Gastric/Gastroesophageal Junction Cancer Recruiting Niraparib MGD013 I Gastric Cancer NCT04178460
triplet drugs Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma Recruiting Olaparib Paclitaxel, Pembrolizumab II Advanced Gastric Adenocarcinoma NCT04209686
Neoadjuvant Chemotherapy With PISOXO for Locally-invaded-gastric Cancer (LIGC) Not yet recruiting Olaparib PIPAC, SOX I/II Locally-invaded-gastric Cancer NCT04410887
Rucaparib Plus Ramucirumab With or Without Nivolumab in Advanced Gastric and Esophageal Adenocarcinoma (RiME) Recruiting Rucaparib Ramucirumab, Nivolumab I/II Advanced Gastric and Esophageal Adenocarcinoma NCT03995017